Urothelial Neoplasms

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2025-09-25
EMA Authorised: Padcev (Enfortumab vedotin) — Astellas Pharma Europe B.V.
The European Medicines Agency authorised Padcev (enfortumab vedotin) for urothelial carcinoma and other urologic neoplasms in the European U…